Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Core Insights - Journey Medical Corporation reported total net product revenues of $13.1 million for Q1 2025, consistent with $13.0 million in Q1 2024, with $2.1 million attributed to the launch of Emrosi [3][15] - The gross margin improved to 64% in Q1 2025 from 54% in the prior year, driven by lower product costs [3] - The company experienced a net loss of $4.1 million, or $(0.18) per share, for Q1 2025, a significant reduction from a net loss of $10.4 million, or $(0.53) per share, in Q1 2024 [3][21] Financial Performance - Cash and cash equivalents increased to $21.1 million as of March 31, 2025, compared to $20.3 million at the end of 2024 [3] - Research and development costs were nil in Q1 2025, down from $7.9 million in Q1 2024, which included pre-approval expenses for Emrosi [3] - Selling, general, and administrative expenses rose by $2.1 million to $10.6 million in Q1 2025, primarily due to activities related to Emrosi's launch [3] Product Launch and Market Position - Emrosi, an oral treatment for rosacea, had a strong launch with initial prescriptions filled in late March 2025 and was included in the updated National Rosacea Society Treatment Algorithms [2][10] - The Phase 3 clinical trial results for Emrosi were published in JAMA Dermatology, demonstrating statistical superiority over Oracea and placebo [2][10] - The company aims for sustainable positive EBITDA and profitability in 2025, viewing it as a transformational year [2] Corporate Developments - Journey Medical appointed Ramsey Alloush as Chief Operating Officer in April 2025 [10] - The company held a conference call on May 14, 2025, to discuss its financial results and strategic objectives [5][6]